Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 240

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease

Open access
Colombel, J-F, Rutgeerts, P, Malchow, H, Jacyna, M, Nielsen, O H, Rask-Madsen, J, Van Deventer, S, Ferguson, A, Desreumaux, P, Forbes, A, Geboes, K, Melani, L, Cohard, M·2001·Gut

Abstract

BACKGROUND AND AIMS: New lesions of Crohn's disease occur early after ileal or ileocolonic resection and ileocolonic anastomosis. We performed a double blind controlled trial to evaluate the safety and tolerance of recombinant human interleukin 10 (IL-10; Tenovil) in subjects operated on for Crohn's disease. We also assessed the effect of Tenovil in preventing endoscopic recurrence 12 weeks after surgery. METHODS: Patients with Crohn's disease who underwent curative ileal or ileocolonic resection and primary anastomosis were randomised within two weeks after surgery to receive subcutaneous Tenovil 4 μg/kg once daily (QD) (n=22) or 8 μg/kg twice weekly (TIW) (n=21), or placebo (QD or TIW) (n=22). An ileocolonoscopy was performed after 12 weeks of treatment. RESULTS: Compliance was excellent. The most frequently observed adverse events were mild and moderate in severity and equally distributed across treatment groups. Thirty seven patients in the pooled Tenovil group and 21 patients in the pooled placebo group were evaluable by endoscopy. At 12 weeks, 11 of 21 patients (52%) in the placebo group had recurrent lesions compared with 17 of 37 patients (46%) in the Tenovil group (ns). The incidence of severe endoscopic recurrence was similar in both groups (9%). CONCLUSION: Tenovil treatment for 12 consecutive weeks in patients with Crohn's disease after intestinal resection was safe and well tolerated. No evidence of prevention of endoscopic recurrence of Crohn's disease by Tenovil was observed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gut.49.1.42

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 240

Metadata

Authors
Colombel, J.-F., Rutgeerts, P., Malchow, H., Jacyna, M., Nielsen, O. H., Rask-Madsen, J., Van Deventer, S., Ferguson, A., Desreumaux, P., Forbes, A., Geboes, K., Melani, L., & Cohard, M.
Venue
Gut
Publisher
BMJ
Published
2001-07-01
Volume
49
Issue
1
Pages
42-46
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2118688515
Cited by
240
References
3
FWCI
8.28
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. https://app.cochat.ai/papers/10.1136/gut.49.1.42
The paper
Colombel, J.-F., Rutgeerts, P., Malchow, H., Jacyna, M., Nielsen, O. H., Rask-Madsen, J., Van Deventer, S., Ferguson, A., Desreumaux, P., Forbes, A., Geboes, K., Melani, L., & Cohard, M. (2001). Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut. https://doi.org/10.1136/gut.49.1.42

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.